Anavex Life Sciences (NASDAQ:AVXL) Receives Buy Rating from D. Boral Capital

Anavex Life Sciences (NASDAQ:AVXL - Get Free Report)'s stock had its "buy" rating reissued by analysts at D. Boral Capital in a research report issued on Monday,Benzinga reports. They presently have a $46.00 price target on the biotechnology company's stock. D. Boral Capital's price target would indicate a potential upside of 336.02% from the stock's current price.

Separately, HC Wainwright lifted their price objective on Anavex Life Sciences from $40.00 to $42.00 and gave the stock a "buy" rating in a report on Thursday, December 26th.

Anavex Life Sciences Stock Down 6.1 %

Anavex Life Sciences stock traded down $0.68 during midday trading on Monday, hitting $10.55. 2,642,727 shares of the stock were exchanged, compared to its average volume of 2,626,646. The stock has a market capitalization of $894.81 million, a price-to-earnings ratio of -21.10 and a beta of 0.70. The business's 50-day moving average price is $9.55 and its 200-day moving average price is $7.06. Anavex Life Sciences has a 52-week low of $3.25 and a 52-week high of $14.44.

Anavex Life Sciences (NASDAQ:AVXL - Get Free Report) last posted its earnings results on Monday, December 23rd. The biotechnology company reported ($0.14) earnings per share for the quarter, topping the consensus estimate of ($0.17) by $0.03. On average, sell-side analysts predict that Anavex Life Sciences will post -0.55 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently bought and sold shares of the company. Barclays PLC grew its holdings in Anavex Life Sciences by 70.4% during the 3rd quarter. Barclays PLC now owns 155,179 shares of the biotechnology company's stock valued at $882,000 after buying an additional 64,101 shares in the last quarter. Charles Schwab Investment Management Inc. lifted its position in shares of Anavex Life Sciences by 2.3% during the third quarter. Charles Schwab Investment Management Inc. now owns 665,976 shares of the biotechnology company's stock worth $3,783,000 after purchasing an additional 14,892 shares during the last quarter. Renaissance Technologies LLC grew its stake in Anavex Life Sciences by 483.8% in the second quarter. Renaissance Technologies LLC now owns 466,437 shares of the biotechnology company's stock worth $1,968,000 after purchasing an additional 386,537 shares in the last quarter. Franklin Resources Inc. increased its position in Anavex Life Sciences by 6.7% during the 3rd quarter. Franklin Resources Inc. now owns 58,557 shares of the biotechnology company's stock valued at $317,000 after purchasing an additional 3,674 shares during the period. Finally, Nwam LLC bought a new position in Anavex Life Sciences in the third quarter worth approximately $5,172,000. 31.55% of the stock is owned by hedge funds and other institutional investors.

About Anavex Life Sciences

Anavex Life Sciences Corp., a clinical stage biopharmaceutical company, engages in the development of therapeutics for the treatment of central nervous system diseases. Its lead product candidate is ANAVEX 2-73 for the treatment of Alzheimer's disease and Parkinson's disease, as well as other central nervous system diseases, including rare diseases, such as Rett syndrome, a rare severe neurological monogenic disorder; and infantile spasms, Fragile X syndrome, and Angelman syndrome.